{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:17:10Z","timestamp":1779927430162,"version":"3.53.1"},"reference-count":25,"publisher":"American Academy of Pediatrics (AAP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"\n OBJECTIVE<\/jats:title>\n Vancomycin carries risks of treatment failure and emergent resistance with underexposure and renal toxicity with overexposure. Children with overweight or obesity may have altered pharmacokinetics. We aimed to examine how body weight metrics influence vancomycin serum concentrations and to evaluate alternative dosing strategies.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n This was a multicenter retrospective cohort study across 3 large, academic hospitals. Patients aged 2 to 18 years old who received \u22653 doses of intravenous vancomycin were included. Weight metrics included total body weight, adjusted body weight, ideal body weight, body surface area, and allometric weight. Outcomes included vancomycin concentration and ratios of area under the curve (AUC) to minimum inhibitory concentration (MIC). Regression analyses were used to examine which body-weight identifier predicted outcomes.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n Of the 1099 children, 45% were girls, mean age was 9.0 (SD = 5.4) years, 14% had overweight, and 17% had obesity. Seventy-five percent of children had vancomycin concentrations in the subtherapeutic range by trough &lt;10 \u00b5g\/mL, and 63% had a ratio of AUC to MIC &lt;400 \u03bcg-hr\/mL. Three percent had a supratherapeutic initial trough &gt;20 \u00b5g\/mL or ratio of AUC to MIC &gt;600 \u03bcg-hr\/mL. Serum vancomycin concentrations were higher in children with overweight or obesity compared with children who were at a normal weight or underweight; the mean ratio of AUC to MIC also trended higher in the groups with overweight or obesity.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n Most children received vancomycin regimens that produced suboptimal trough levels. Children with overweight or obesity experienced higher vancomycin trough levels than children of normal weight despite receiving lower total body weight dosing. Using the ratio of AUC to MIC was a better measure of drug exposure.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/hpeds.2020-004465","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T09:35:18Z","timestamp":1635759318000},"page":"e289-e296","source":"Crossref","is-referenced-by-count":4,"title":["A Multicenter Retrospective Study of Vancomycin Dosing by Weight Measures in Children"],"prefix":"10.1542","volume":"11","author":[{"given":"Manaswitha","family":"Khare","sequence":"first","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of California, San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith B.","family":"Haag","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oregon Health and Science University and Doernbecher Children\u2019s Hospital, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Kneese","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Texas Health San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared P.","family":"Austin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oregon Health and Science University and Doernbecher Children\u2019s Hospital, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Perlman","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Texas Health San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniqa","family":"Azim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oregon Health and Science University and Doernbecher Children\u2019s Hospital, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carisse","family":"Orsi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, University of Texas Health San Antonio, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron A.","family":"Foster","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oregon Health and Science University and Doernbecher Children\u2019s Hospital, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"issue":"2","key":"2021121010310875600_b1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1467-789X.2009.00712.x","article-title":"The economic burden of obesity worldwide: a systematic review of the direct costs of obesity","volume":"12","author":"Withrow","year":"2011","journal-title":"Obes Rev"},{"key":"2021121010310875600_b2","doi-asserted-by":"crossref","first-page":"W4-480","DOI":"10.1377\/hlthaff.W4.480","article-title":"The impact of obesity on rising medical spending","author":"Thorpe","year":"2004","journal-title":"Health Aff (Millwood)"},{"issue":"9331","key":"2021121010310875600_b3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(02)09678-2","article-title":"Childhood obesity: public-health crisis, common sense cure","volume":"360","author":"Ebbeling","year":"2002","journal-title":"Lancet"},{"issue":"288","key":"2021121010310875600_b4","first-page":"1","article-title":"Prevalence of obesity among adults and youth: United States, 2015-2016","author":"Hales","year":"2017","journal-title":"NCHS Data Brief"},{"issue":"16","key":"2021121010310875600_b5","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.2018.3060","article-title":"Trends in obesity and severe obesity prevalence in US youth and adults by sex and age, 2007-2008 to 2015-2016","volume":"319","author":"Hales","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"2021121010310875600_b6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/pan.12396","article-title":"A retrospective description of anesthetic medication dosing in overweight and obese children","volume":"24","author":"Burke","year":"2014","journal-title":"Paediatr Anaesth"},{"issue":"10","key":"2021121010310875600_b7","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/sj.ijo.0803402","article-title":"Body composition in normal weight, overweight and obese children: matched case-control analyses of total and regional tissue masses, and body composition trends in relation to relative weight","volume":"30","author":"Wells","year":"2006","journal-title":"Int J Obes"},{"issue":"7","key":"2021121010310875600_b8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jamapediatrics.2015.132","article-title":"Drug dosing and pharmacokinetics in children with obesity: a systematic review","volume":"169","author":"Harskamp-van Ginkel","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"5","key":"2021121010310875600_b9","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1542\/hpeds.2014-0081","article-title":"An evaluation of vancomycin dosing for complicated infections in pediatric patients","volume":"5","author":"Durham","year":"2015","journal-title":"Hosp Pediatr"},{"issue":"12","key":"2021121010310875600_b10","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/phar.1345","article-title":"Vancomycin dosing in children and young adults: back to the drawing board","volume":"33","author":"Camaione","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2021121010310875600_b11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/phar.1552","article-title":"Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study","volume":"35","author":"Matson","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"12","key":"2021121010310875600_b12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/phar.1321","article-title":"Vancomycin trough concentrations in overweight or obese pediatric patients","volume":"33","author":"Heble","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"5","key":"2021121010310875600_b13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2174\/157488612805076606","article-title":"Prospective evaluation of the dosing regimen of vancomycin in children of different weight categories","volume":"7","author":"Nassar","year":"2012","journal-title":"Curr Drug Saf"},{"issue":"5","key":"2021121010310875600_b14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/0009922810393500","article-title":"Vancomycin dosing in obese pediatric patients","volume":"50","author":"Moffett","year":"2011","journal-title":"Clin Pediatr (Phila)"},{"issue":"21","key":"2021121010310875600_b15","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.2146\/ajhp110107","article-title":"Vancomycin dosage in overweight and obese children","volume":"68","author":"Miller","year":"2011","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"2021121010310875600_b16","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.clinthera.2015.05.006","article-title":"Bayesian estimation of vancomycin pharmacokinetics in obese children: matched case-control study","volume":"37","author":"Le","year":"2015","journal-title":"Clin Ther"},{"issue":"3","key":"2021121010310875600_b17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/jpids\/piaa057","article-title":"Executive summary: therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: a revised consensus guideline and review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"9","author":"Rybak","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"246","key":"2021121010310875600_b18","first-page":"1","article-title":"2000 CDC growth charts for the United States: methods and development","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Stat 11"},{"issue":"17","key":"2021121010310875600_b19","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med"},{"issue":"1","key":"2021121010310875600_b20","first-page":"107","article-title":"Estimating ideal body mass in children","volume":"40","author":"Traub","year":"1983","journal-title":"Am J Hosp Pharm"},{"issue":"2","key":"2021121010310875600_b21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","article-title":"What is the best size descriptor to use for pharmacokinetic studies in the obese?","volume":"58","author":"Green","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2021121010310875600_b22","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","author":"Le","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"2021121010310875600_b23","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/phar.1331","article-title":"The effect of age and weight on vancomycin serum trough concentrations in pediatric patients","volume":"33","author":"Madigan","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2021121010310875600_b24","first-page":"182","article-title":"Vancomycin dosing in healthy-weight, overweight, and obese pediatric patients","volume":"19","author":"Eiland","year":"2014","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"4","key":"2021121010310875600_b25","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/jpc.14683","article-title":"Vancomycin therapeutic drug monitoring in paediatrics","volume":"56","author":"Patel","year":"2020","journal-title":"J Paediatr Child Health"}],"container-title":["Hospital Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/11\/11\/e289\/1191948\/hpeds_2020-004465.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article-pdf\/11\/11\/e289\/1191948\/hpeds_2020-004465.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T23:08:21Z","timestamp":1639177701000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/hospitalpediatrics\/article\/11\/11\/e289\/181228\/A-Multicenter-Retrospective-Study-of-Vancomycin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.1542\/hpeds.2020-004465","relation":{},"ISSN":["2154-1663","2154-1671"],"issn-type":[{"value":"2154-1663","type":"print"},{"value":"2154-1671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]}}}